


Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways

This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.

This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.



160,49 €

149,99 € (zzgl. MwSt.)

Lieferfrist: bis zu 10 Tage

Artikelnummer: 9783030098179

Medium: Buch

ISBN: 978-3-030-09817-9

Verlag: Springer International Publishing

Erscheinungstermin: 02.02.2019

Sprache(n): Englisch

Auflage: Softcover Nachdruck of the original 1. Auflage 2018

Serie: Resistance to Targeted Anti-Cancer Therapeutics

Produktform: Kartoniert

Gewicht: 406 g

Seiten: 242

Format (B x H): 155 x 235 mm

